Molina-Cerrillo J - Search Results

1

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.

Santoni M, Massari F, Takeshita H, Tapia JC, Dionese M, Pichler R, Rizzo M, Lam ET, Grande E, Kemp R, Molina-Cerrillo J, Calabrò F, Tural D, Küronya Z, Kucharz J, Fiala O, Seront E, Kopp RM, Abahssain H, Kopecky J, Martignetti A, Kanesvaran R, Zakopoulou R, Ansari J, Landmesser J, Mollica V, Porta C, Bellmunt J, Salah S, Santini D. Santoni M, et al. Among authors: molina cerrillo j. Clin Exp Med. 2023 Dec;23(8):5413-5422. doi: 10.1007/s10238-023-01235-6. Epub 2023 Nov 2. Clin Exp Med. 2023. PMID: 37917218

2

Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?

Molina-Cerrillo J, Martínez-Sáez O, Alonso-Gordoa T, Tirado-Zambrano P, Delgado-Vargas B, Earl J, Grande E. Molina-Cerrillo J, et al. Clin Genitourin Cancer. 2015 Dec;13(6):493-8. doi: 10.1016/j.clgc.2015.05.001. Epub 2015 May 13. Clin Genitourin Cancer. 2015. PMID: 26027772 Review.

3

Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.

Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Molina-Cerrillo J, et al. Oncologist. 2016 Jun;21(6):701-7. doi: 10.1634/theoncologist.2015-0455. Epub 2016 Apr 22. Oncologist. 2016. PMID: 27107003 Free PMC article. Review.

4

Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.

Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. Martínez-Sáez O, et al. Crit Rev Oncol Hematol. 2017 Mar;111:117-123. doi: 10.1016/j.critrevonc.2017.01.013. Epub 2017 Jan 28. Crit Rev Oncol Hematol. 2017. PMID: 28259286 Review.

5

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Molina-Cerrillo J, et al. Cancer Treat Rev. 2017 Jul;58:41-50. doi: 10.1016/j.ctrv.2017.06.001. Epub 2017 Jun 9. Cancer Treat Rev. 2017. PMID: 28641100 Review.

6

Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Gajate P, Alonso-Gordoa T, Martínez-Sáez O, Molina-Cerrillo J, Grande E. Gajate P, et al. Clin Transl Oncol. 2018 May;20(5):561-569. doi: 10.1007/s12094-017-1758-3. Epub 2017 Nov 9. Clin Transl Oncol. 2018. PMID: 29124519 Review.

7

Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.

Molina-Cerrillo J, Grande E, Alonso-Gordoa T. Molina-Cerrillo J, et al. Oncologist. 2019 Jul;24(7):e597-e599. doi: 10.1634/theoncologist.2018-0776. Epub 2019 Mar 15. Oncologist. 2019. PMID: 30877189 Free PMC article.

8

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".

Alonso-Gordoa T, García-Bermejo ML, Grande E, Garrido P, Carrato A, Molina-Cerrillo J. Alonso-Gordoa T, et al. Int J Mol Sci. 2019 Apr 17;20(8):1901. doi: 10.3390/ijms20081901. Int J Mol Sci. 2019. PMID: 30999623 Free PMC article. Review.

9

In Reply.

Grande E, Molina-Cerrillo J, Alonso-Gordoa T. Grande E, et al. Oncologist. 2020 Aug;25(8):e1259. doi: 10.1634/theoncologist.2020-0336. Epub 2020 Jun 16. Oncologist. 2020. PMID: 32436340 Free PMC article.

10

Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation.

Molina-Cerrillo J, Alonso-Gordoa T, Carrato A, Grande E. Molina-Cerrillo J, et al. Oncotarget. 2020 Jun 2;11(22):2137-2140. doi: 10.18632/oncotarget.27598. eCollection 2020 Jun 2. Oncotarget. 2020. PMID: 32547710 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page